SEC Form 4 · accession 0001104659-17-056611
SUPERNUS PHARMACEUTICALS, INC. · SUPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory S Patrick
Officer — VP, Chief Financial Officer
Period of report
Sep 7, 2017
Accepted (ET)
Sep 11, 2017 · 7:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001356576
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 7, 2017 | M | 26,519 | $7.90 | A | 27,235 | D | |
| Common StockF3 | Sep 7, 2017 | S | 25,000 | $46.3561 | D | 2,235 | D | |
| Common Stock | Sep 7, 2017 | S | 1,519 | $48.00 | D | 716 | D | |
| Common Stock | Sep 7, 2017 | M | 15,000 | $5.88 | A | 15,716 | D | |
| Common Stock | Sep 8, 2017 | M | 23,481 | $7.90 | A | 39,197 | D | |
| Common StockF4 | Sep 8, 2017 | S | 23,481 | $48.8891 | D | 15,716 | D | |
| Common Stock | Sep 8, 2017 | M | 15,000 | $5.88 | A | 30,716 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F5 | $7.90 | Sep 7, 2017 | M | 26,519 | D | — | Feb 5, 2023 | Common Stock | 26,519 | 43,481 | D |
| Employee Stock Option (Right to Buy)F6 | $5.88 | Sep 7, 2017 | M | 15,000 | D | — | Dec 30, 2021 | Common Stock | 15,000 | 40,000 | D |
| Employee Stock Option (Right to Buy)F5 | $7.90 | Sep 8, 2017 | M | 23,481 | D | — | Feb 5, 2023 | Common Stock | 23,481 | 20,000 | D |
| Employee Stock Option (Right to Buy)F6 | $5.88 | Sep 8, 2017 | M | 15,000 | D | — | Dec 30, 2021 | Common Stock | 15,000 | 25,000 | D |
Explanation of responses
- F1Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017.
- F2Includes an aggregate of 495 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.0000 to $47.3500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.6000 to $49.3500, inclusive. The reporting person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
- F5The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted.
- F6The option became exercisable in four equal installments beginning on December 30, 2012, which was the first anniversary of the date on which the option was granted.